Atrial fibrillation: diagnosis and management

falls to ensure that anticoagulation is offered in this population when needed. The benefits and harms should be discussed with the person. How the recommendations might affect practice The recommendations are likely to lead to a change in current practice, with a reduction in warfarin use. The committee noted that this has been a prescribing trend over recent years and it may lead to a contraction in warfarin clinic services. The unit cost of direct-acting anticoagulants is greater than that for warfarin, so there is likely to be a resource impact from increased use of direct-acting anticoagulants. Return to recommendations Rate control Recommendations 1.7.2 to 1.7.6 Why the committee made the recommendations The committee made some updates to the 2014 recommendations, based on their experience and knowledge. The use of beta-blockers or rate-limiting calcium-channel blockers for initial rate-control treatment was retained by the committee because this is current practice and there was insufficient evidence to suggest an alternative option. The committee agreed that the choice of treatment should still be made based on the symptoms, heart rate, comorbidities and preferences of those being treated. The committee agreed that the recommendations should refer to NICE's guideline on chronic heart failure for
